Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenqi Yanshen Keli (参芪延肾颗粒) is a traditional Chinese medicine (TCM) formulation developed as an innovative Class 1.1 Chinese herbal drug. It is designed for the treatment of chronic glomerulonephritis, a type of chronic kidney disease. The product is an optimized hospital preparation with established human use experience and some clinical efficacy and safety data from preclinical pharmacological and toxicological studies. Its mechanism of action is based on TCM principles, primarily aiming to tonify Qi (vital energy), nourish the kidneys, and support overall renal function through multi-component herbal synergy. The specific active ingredients are not detailed in available sources but typically include herbs such as ginseng (Ren Shen), astragalus (Huang Qi), among others commonly used in similar formulations for kidney health[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shenqi Yanshen Keli.